代谢功能障碍相关脂肪性肝病与非酒精性脂肪性肝病的临床特征和死亡率相似
研究比较代谢功能障碍相关脂肪性肝病(MASLD)与非酒精性脂肪性肝病(NAFLD)的临床特征和结局,使用三级医疗数据库和NHANES数据。结果显示绝大多数NAFLD患者符合MASLD标准,无创检测预测准确性相同,MASLD患者死亡率略高但归因于心血管代谢风险因素,提示两种术语可互换使用。
要点
- NAFLD数据库中99%患者符合MASLD标准,95%仅基于BMI即符合。
- NHANES人群中MASLD与NAFLD诊断高度一致,Cohen's kappa系数0.968。
- 中位随访22.83年,MASLD与NAFLD诊断间死亡率无差异(P值≥0.05)。
核心结论
- NAFLD与MASLD临床特征和无创检测阈值相同,MASLD患者似乎年龄更大且死亡风险略高,可能归因于心血管代谢风险因素。
- 这些数据提供证据表明NAFLD和MASLD术语可互换使用;对于不符合MASLD标准的小部分NAFLD患者需进一步考虑。
研究设计与样本
- 比较数据来自本院NAFLD数据库和美国国家健康与营养调查(NHANES III),死亡率数据来自NHANES-国家死亡索引。
- NAFLD数据库纳入6,429例患者,NHANES纳入12,519名符合条件参与者。
- 采用Cox比例风险回归模型评估全因死亡率,竞争风险分析评估病因特异性死亡率。
主要发现
- NAFLD数据库患者年龄54±12岁,42%男性,BMI 35.4±8.3,腰围112±17 cm,52%患2型糖尿病。
- NAFLD数据库平均ELF评分9.6±1.2,FIB-4 1.69±1.24,肝脏硬度14.0±11.8 kPa;99%符合MASLD标准,95%仅基于BMI符合MASLD。
- ELF和FIB-4在MASLD与NAFLD间的预测准确性相同;NHANES中MASLD与NAFLD诊断高度一致,Cohen's kappa系数0.968(95% CI 0.962-0.973),5.29%的NAFLD病例不符合MASLD标准。
- NHANES参与者年龄43.00岁,47.38%男性,22.70%肥胖,7.28%患2型糖尿病,82.51%有至少1项心血管代谢标准。
- 中位随访22.83年后,MASLD与NAFLD诊断间无死亡率差异(P值≥0.05)。
关键数值与推荐
- MASLD与NAFLD诊断一致性Cohen's kappa系数0.968(95% CI 0.962-0.973)。
- NAFLD数据库中99%符合MASLD标准,95%仅基于BMI符合MASLD标准。
- 5.29%的NAFLD病例不符合MASLD标准。
临床怎么用
- 原文未据此给出推荐。
- 作者认为NAFLD和MASLD术语可互换使用,过去三十年针对NAFLD生成的数据可用于MASLD。
- 作者指出对于不符合MASLD标准的小部分NAFLD患者需进一步考虑。
局限性
- MASLD患者似乎年龄更大且死亡风险略高,可能归因于心血管代谢风险因素。
- 对于不符合MASLD标准的小部分NAFLD患者需进一步考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Recently, the term metabolic dysfunction-associated steatotic liver disease (MASLD) has replaced non-alcoholic fatty liver disease (NAFLD). Concern remains regarding whether the evidence generated under the NAFLD definition can be used for MASLD. We compared the clinical profile and outcomes of NAFLD to MASLD using tertiary care- and population-based data. METHODS: Comparison data were obtained from our NAFLD database and the National Health and Nutrition Examination Survey (NHANES III). Clinical profiles and non-invasive tests (enhanced liver fibrosis [ELF] score, fibrosis-4 index [FIB-4] and vibration-controlled transient elastography) were compared. Mortality data were obtained from NHANES-National Death Index. All-cause mortality was assessed by Cox proportional hazards regression models and cause-specific mortality by competing risk analysis. RESULTS: There were 6,429 patients in the NAFLD database (age: 54 ± 12 years, 42% male, BMI 35.4 ± 8.3, waist circumference 112 ± 17 cm, 52% type 2 diabetes). Average scores for ELF, FIB-4 and liver stiffness were 9.6 ± 1.2, 1.69 ± 1.24,14.0 ± 11.8 kPa, respectively; 99% met MASLD criteria; 95% met MASLD on BMI only. Predictive accuracy of ELF and FIB-4 were identical between MASLD and NAFLD. We included 12,519 eligible participants from NHANES (age 43.00 years, 47.38% male, 22.70% obese, 7.28% type 2 diabetes, 82.51% ≥1 cardiometabolic criteria). Among the NHANES study population, there was excellent concordance between MASLD and NAFLD diagnoses: Cohen's kappa coefficient: 0.968 (95% CI 0.962-0.973) with 5.29% of NAFLD cases not meeting MASLD criteria. After a median follow-up of 22.83 years, there were no mortality differences between MASLD and NAFLD diagnoses (p values ≥0.05). CONCLUSIONS: NAFLD and MASLD are similar except individuals with MASLD seem to be older with slightly higher mortality risk, likely owing to cardiometabolic risk factors. Clinical profiles and non-invasive test thresholds were also identical. These data provide evidence that NAFLD and MASLD terminologies can be used interchangeably. For the small proportion of patients with NAFLD who do not meet MASLD criteria, further consideration is needed. IMPACT AND IMPLICATIONS: In June 2023, new terminology (MASLD) was adopted to replace the term NAFLD as a means to better describe what the liver disease is rather than what it is not, as well as to potentially reduce stigma. Given that MASLD requires at least one cardiometabolic risk factor, questions were raised as to whether this change in the definition would nullify the similarities between NAFLD and MASLD and require new evidence to be generated for MASLD. We used our NAFLD database and a US population-based database to show that the vast majority of patients with NAFLD fulfill criteria for MASLD. Non-invasive tests performed similarly in both groups. Mortality risk was slightly higher in those with MASLD, which is attributed to the presence of cardiometabolic risks. These results provide evidence that data generated in the past three decades for NAFLD can be used interchangeably for MASLD.
引用
- Younossi ZM, Paik JM, Stepanova M, et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024. PMID: 38286339. doi:10.1016/j.jhep.2024.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。